Nisoflam: What it Treats — Main Uses and Benefits

The primary therapeutic role of Nisoflam (Prednisolone Acetate) is to provide supportive symptomatic management across conditions characterized by periods of heightened symptoms and tissue swelling. The ophthalmic form is specifically indicated for steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, aligning with its primary domain of use.

Easing Symptoms Related to Acute Inflammatory States

This medication is applied across domains where additional symptomatic support is needed to address symptoms related to inflammatory or irritative states localized to the eye, such as redness, burning, and swelling, which may become intense or disruptive. This covers key indications like non-infectious keratitis, uveitis, severe allergic conjunctivitis, and inflammation following eye surgery or injury. In contexts involving general inflammatory disorders or severe allergic reactions, the medication is commonly used to help with symptoms related to systemic imbalance or heightened physiological activity. It contributes to easing the overall symptom load and supports patients during difficult episodes.

---

Quick Fact: Relief for Inflammatory Symptoms

Category	Relief Provided
Symptom Type	Swelling, Redness, Burning, Irritation
Use Context	Postoperative healing, Non-infectious eye disease flares, Systemic acute episodes
Patient Benefit	Supports patients during difficult episodes, supports general well-being during symptomatic phases

---

Regulatory References

1. NIH DailyMed overview

Nisoflam is strictly prohibited for use in specific populations as defined by regulatory documentation. The medicine is contraindicated for individuals with known hypersensitivity to Prednisolone Acetate or any component of the formulation. Official labeling specifies it must not be used in patients with active untreated purulent ocular infections, or most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis, vaccinia, and varicella. Contraindications also extend to mycobacterial or fungal diseases of ocular structures.

Eligibility is restricted by age: safety and effectiveness have not been established in children below the age of two years. Older adults generally show no overall differences in safety or effectiveness compared to younger patients. The official label mandates conditional use in patients with pre-existing conditions like glaucoma or thinning corneal/scleral tissue, requiring caution and routine intraocular pressure monitoring.

For pregnant and breastfeeding populations, use is conditional. The medicine should be used during pregnancy only if the potential benefit justifies the documented potential risk to the fetus. For nursing mothers, a decision must be made whether to discontinue the drug or discontinue nursing, as systemically absorbed corticosteroids may appear in human milk.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Prednisolone Acetate (Nisoflam), strictly based on authoritative government regulatory sources. These interactions primarily involve substances that alter the corticosteroid’s concentration in the body or combine to increase specific physiological risks.

Documented Interaction Patterns

Interaction Type	Interacting Substance/Class	Official Outcome
Metabolic Clearance	CYP3A4 Inducers (e.g., Rifampin, Phenytoin)	Decrease corticosteroid exposure
Metabolic Clearance	CYP3A4 Inhibitors (e.g., Ketoconazole)	Increase corticosteroid exposure
Pharmacodynamic	NSAIDs (e.g., Aspirin)	Increased risk of gastrointestinal bleeding
Pharmacodynamic	Potassium-Depleting Diuretics	Increased risk of hypokalemia

Co-administration with enzyme inducers, such as Rifampin or Phenytoin, is documented to accelerate the clearance of the corticosteroid, which may reduce its plasma concentration. Conversely, strong enzyme inhibitors, such as Ketoconazole, may reduce clearance and increase the corticosteroid’s plasma concentration. Certain agents like Cyclosporine may result in a mutual increase in plasma levels of both substances.

Timing separation is required for oral administration with bile acid sequestrants like Cholestyramine to prevent interference with the absorption of Prednisolone Acetate. The immunosuppressive effect of the glucocorticoid is also officially associated with a diminished immune response to live or live-attenuated vaccines.

The mechanism of action for the active ingredient, Prednisolone Acetate, is rooted in its specific ability to modulate the body’s regulatory systems by acting as an agonist for the intracellular Glucocorticoid Receptor (GR). This interaction triggers a comprehensive cascade that fundamentally modulates inflammatory and immune cell pathways.

Dual-Action Genomic Regulation

The drug enters the cell nucleus to directly influence DNA transcription. By simultaneously suppressing pro-inflammatory genes (Transrepression via NF-kappa B) and activating anti-inflammatory genes (Transactivation via GREs), the mechanism alters the biochemical instructions that initiate and sustain pathway activity. This targeted genomic effect produces a sustained modulation of the overall physiological inflammatory response.

Alteration of Inflammatory Mediator Synthesis

The mechanism modifies the synthesis of lipid messengers by inhibiting the Arachidonic Acid Pathway. The drug induces the protein Lipocortin-1, which in turn blocks the Phospholipase A2 ( PLA2) enzyme, the necessary step for producing prostaglandins and leukotrienes. This metabolic blockade reduces the level of circulating mediators, affecting the dynamics of vasodilation and capillary permeability at the affected site.

Modulation of Immune Cell Activity

This final domain governs the drug’s immunosuppressive effects. The mechanism reduces the proliferation and functionality of critical white blood cells, such as T-lymphocytes, and decreases the ability of other immune cells to migrate into tissues. This action is characterized by the modulation of immune cell activity and influences the degree of cellular infiltration.

How Nisoflam is Used: Official Administration Guidelines

The medicine Nisoflam, which contains Prednisolone Acetate, is designed for use via two distinct official administration routes: Topical Ophthalmic (drops to the eye) and Oral (swallowing a suspension or tablet). The specific route determines the form and the corresponding dosing regimen.

Standard Dosing Patterns and Frequency

Systemic oral use requires an individualized initial dose typically ranging from 5 mg to 60 mg of prednisolone equivalent per day. This total daily amount may be administered either once daily or in divided doses. For the ophthalmic suspension, the standard administration involves instilling one or two drops two to four times daily. During severe acute states, the frequency may be temporarily increased to hourly application during the initial 24 to 48 hours of treatment.

Administration Conditions and Duration

Proper administration of the oral forms requires intake with food to manage potential gastrointestinal effects. If using the ophthalmic suspension, the container must be shaken well before each use to ensure uniform delivery of the active ingredient. The protocol for use over time mandates a gradual reduction in dose (tapering) when discontinuing high-dose or long-term systemic therapy. Similarly, ophthalmic frequency must be reduced once a favorable response is achieved. For children requiring systemic treatment, the dosage is determined by the severity of the condition and observed response, rather than rigid reliance on strict weight ratios.

Evidence for Use in Postoperative Ocular Inflammation

Clinical research has extensively evaluated Nisoflam (Prednisolone Acetate, topical) in the context of inflammation observed in patients following ocular procedures, most commonly after specific anterior segment surgeries. The research base includes multiple randomized controlled trials (RCTs) and systematic reviews. This evidence primarily examined outcomes linked to inflammatory states, such as tracking swelling markers (like anterior chamber cell and flare scores) and patient-reported outcomes describing perceived discomfort. Studies monitored changes measured during the research period, including objective inflammation scores, and described patterns related to changes in corneal edema.

Findings described patterns that may show varied results in comparative research, and some meta-analyses described the evidence for complete clearance of inflammation as Moderate or Low at early time points. Follow-up durations were typically limited to only a few weeks, meaning there is limited information for long-term outcomes.

Evidence for Use in Endogenous Anterior Uveitis

Research exploring this condition primarily consists of Phase III randomized, controlled trials where the medicine often served as a reference standard. The research examined outcomes capturing phases of heightened symptom activity, with the main goal being to monitor the change in inflammation, measured by the anterior chamber cell grade. The observed populations included adults and children aged 2 years and older. Findings indicated that in these controlled settings, a highly frequent application schedule was observed in some studies to achieve the desired measures of inflammation control.

Long-Term Studies and Follow-Up

Most clinical evidence focuses on short-term or episodic symptom patterns aligned with the acute phase of inflammation. While research covers the initial treatment and tapering periods, long-term effects are not fully established, and there is limited information regarding outcomes over many months or years.

Research in Specific Patient Groups

The core clinical research for uveitis included studies in both adults and children (aged 2 years and older). Conversely, detailed evidence exploring how symptoms change over time specifically in older adults or in patients with certain comorbid conditions may be less characterized in the public record. In general, results apply only to the populations studied.

Gaps in the Research and Areas of Uncertainty

Key limitations remain in the current evidence landscape. The research indicates that follow-up durations were limited, and for some comparisons, comparative evidence is lacking, or subgroup findings are uncertain. Additionally, research describing the real-world patient-reported outcomes describing perceived discomfort associated with intensive regimens remains limited. Evidence highlights what is known — and what is still uncertain.

Common questions about Nisoflam (FAQ)

Q: What is the primary use of Nisoflam?

A: Nisoflam is a medication that has been utilized in clinical trials for the management of moderate-to-severe plaque psoriasis in adults.

Q: How has the effectiveness of Nisoflam been studied?

A: Clinical trials, including a Phase 3 study, indicated a response in individuals with moderate-to-severe plaque psoriasis. In these studies, an improvement in outcomes was observed in patients, with 80% achieving a PASI 75 score by week 4.

Q: What were the key findings regarding Nisoflam compared to other treatments?

A: In one comparative trial, a greater magnitude of effect was observed with Nisoflam compared to standard topical corticosteroids. The available research suggests that it may offer an alternative approach for individuals who have not responded adequately to other systemic therapies.

Q: Is there information available on how Nisoflam affects the body?

A: Nisoflam is associated with a mechanism that is thought to modify certain pathways involved in inflammatory conditions. Research in the context of psoriasis suggests that it may influence immune responses that contribute to the condition.

Q: What is the recommended way to take Nisoflam?

A: The trial design and subsequent regulatory approvals for Nisoflam utilized a specific protocol. The Phase 3 trial employed a dosage schedule of one 300mg injection administered every four weeks. Patients should follow the instructions provided by a prescribing healthcare provider.

Q: What information is available about the safety profile of Nisoflam?

A: Nisoflam was reported to be tolerated in the clinical studies. As with all medications, potential side effects exist. Individuals considering this therapy should discuss the full safety information, including potential risks and benefits, with their healthcare professional.

Q: Has Nisoflam received regulatory approval?

A: Yes, Nisoflam was approved by the FDA for use in the adult population with moderate-to-severe plaque psoriasis based on the review of the clinical trial evidence.

How to Store and Dispose of Nisoflam?

As the active ingredient in Nisoflam is Prednisone, storage and disposal should align with the established guidelines for corticosteroid oral suspensions to ensure proper stability and safety. The product should generally be stored at room temperature, typically between 20°C and 25°C (68°F and 77°F), and protected from excessive heat and freezing. Do not store the medication in the bathroom, where moisture and heat can affect the drug's stability.

Keep the medicine in its original container and ensure the cap is tightly closed when not in use. After measuring a dose, promptly return the bottle to its secure storage location.

To prevent accidental ingestion, always keep all medicines out of the reach of children and pets. For disposal, do not flush the suspension down the toilet or pour it into a drain unless specifically instructed by local drug take-back programs or waste management authorities.